# Multitarget stool DNA testing for colorectal-cancer screening

Source: https://onco.cc/key-papers/paper-deep-c-n-engl-j-med-2014/  
OnCo record `paper-deep-c-n-engl-j-med-2014` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the DeeP-C trial registered as NCT01397747, in New England Journal of Medicine (2014), chosen as the most cited paper whose own text cites the registry id.

## Summary

Background: An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening.

Methods: We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings.

Results: Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the greatest dimension) on colonoscopy. The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P=0.002). The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT (P=0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT were 86.6% and 94.9%, respectively, among participants with nonadvanced or negative findings (P<0.001) and 89.8% and 96.4%, respectively, among those with negative results on colonoscopy (P<0.001). The numbers of persons who would need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA testing, and 208 with FIT.

Conclusions: In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.).

Indexed on Europe PMC as PubMed record 24645800 (DOI 10.1056/nejmoa1311194). Its abstract cites the registry id NCT01397747, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: New England Journal of Medicine
- Year: 2014
- DOI: 10.1056/nejmoa1311194
- Authors: Imperiale TF, Ransohoff DF, Itzkowitz SH, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT01397747 with the most citations, so it is the natural first reading for anyone following the DeeP-C trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- N Engl J Med 2014: https://doi.org/10.1056/nejmoa1311194
- PubMed: https://pubmed.ncbi.nlm.nih.gov/24645800/
- Europe PMC: https://europepmc.org/article/MED/24645800
- ClinicalTrials.gov NCT01397747: https://clinicaltrials.gov/study/NCT01397747

## Connected records

- trials: [DeeP-C](https://onco.cc/trials/deep-c/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)

---
JSON: https://onco.cc/api/v1/entities/paper-deep-c-n-engl-j-med-2014.json